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Abstract
Background Severe traumatic brain injury (TBI) has been
increasing with greater incidence of injuries from traffic or
sporting accidents. Although there are a number of animal
models of TBI using progesterone for head injury, the effects of
progesterone on neurologic outcome of acute TBI patients
remain unclear. The aim of the present clinical study was to
assess the longer-term efficacy of progesterone on the
improvement in neurologic outcome of patients with acute
severe TBI.
Methods A total of 159 patients who arrived within 8 hours of
injury with a Glasgow Coma Score ≤ 8 were enrolled in the
study. A prospective, randomized, placebo-controlled trial of
progesterone was conducted in the Neurotrauma Center of our
teaching hospital. The patients were randomized to receive
either progesterone or placebo. The primary endpoint was the
Glasgow Outcome Scale score 3 months after brain injury.
Secondary efficacy endpoints included the modified Functional
Independence Measure score and mortality. In a follow-up
protocol at 6 months, the Glasgow Outcome Scale and the
modified Functional Independence Measure scores were again
determined.
Results Of the 159 patients randomized, 82 received
progesterone and 77 received placebo. The demographic
characteristics, the mechanism of injury, and the time of
treatment were compared for the two groups. After 3 months
and 6 months of treatment, the dichotomized Glasgow
Outcome Scale score analysis exhibited more favorable
outcomes among the patients who were given progesterone
compared with the control individuals (P  = 0.034 and P  =
0.048, respectively). The modified Functional Independence
Measure scores in the progesterone group were higher than
those in the placebo group at both 3-month and 6-month follow-
up (P  < 0.05 and P  < 0.01). The mortality rate of the
progesterone group was significantly lower than that of the
placebo group at 6-month follow-up (P  < 0.05). The mean
intracranial pressure values 72 hours and 7 days after injury
were lower in the progesterone group than in the placebo group,
but there was no statistical significance between the two groups
(P  > 0.05). Instances of complications and adverse events
associated with the administration of progesterone were not
found.
Conclusion Our data suggest that acute severe TBI patients
with administration of progesterone hold improved neurologic
outcomes for up to 6 months. These results provide information
important for further large and multicenter clinical trials on
progesterone as a promising neuroprotective drug.
Trial Registration ACTRN12607000545460.
FIM = Functional Independence Measure; GCS = Glasgow Coma Scale; GOS = Glasgow Outcome Scale; ICP = intracranial pressure; TBI = trau-
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Introduction
Traumatic brain injury (TBI) remains one of the leading causes
of injury-related death and severe disability. The management
of TBI currently includes preventing further neurological
insults, managing the intracranial pressure (ICP), and surgical
procedures. It is very important to search for clinically effective
neuroprotective drugs to prevent secondary brain injury after
TBI. In spite of many neuroprotective agents showing efficacy
in experimental models of TBI, none has produced significant
neuronal protection when tested in clinical trials [1,2].
Progesterone, a hormone, has steroidal, neuroactive and neu-
rosteroidal action in the center neuronal system. Neuroprotec-
tive effects of progesterone have recently been shown in a
variety of animal models, including ischemic and traumatic
brain insult models [3-6]. Postinjury administration of proges-
terone in experimental models of head injury confers signifi-
cant protection against TBI-induced cerebral edema and
secondary neuronal death, promoting behavioral recovery
[7,8]. Experimental evidence suggests that postinjury treat-
ment with progesterone decreases brain edema, attenuates
free radical damage, and reduces neuronal loss in TBI animal
models [8-13]. Progesterone also reduces the inflammatory
response and attenuates neurological abnormalities after
ischemia and spinal cord injury [14-18].
In a recently published controlled study of progesterone,
Wright and colleagues conducted a phase II, randomized,
double-blind, placebo-controlled trial to assess the safety and
benefit of administering progesterone to patients with acute
TBI [19]. No serious adverse events were found in the 77
patients who received progesterone, and the patients with
moderate TBI who received progesterone were more likely to
have a moderate to good outcome than those were rand-
omized to placebo at 30 days post injury. The 30-day mortality
in the progesterone group was less than one-half that of the
control group. This outcome suggests that progesterone
causes no harms and may be a beneficial treatment for TBI
[19].
Despite these potential advantages and the good safety pro-
file of progesterone described in studies utilizing animals or
humans as subjects, there is relatively little information availa-
ble from assessing neuroprotective properties of progester-
one in the patients with acute severe brain trauma. The effects
of progesterone on neurological outcome of the TBI patients
remain unclear. The purpose of the present pilot clinical study
was to assess the longer-term efficacy of progesterone on
improving the neurological outcome of patients with acute
severe TBI.
Materials and methods
Patients
Patients with acute severe TBI and a Glasgow Coma Scale
(GCS) score ≤ 8 after resuscitation and stabilization were
entered into the study. Two hundred and thirty patients from
the Neurotrauma Center of our teaching hospital were
included. Male or female patients between the ages of 18 and
65 years were studied. The patients received progesterone
within 8 hours after the documented time of injury. All patients
admitted to the Neurotrauma Center, Clinical Medical College
of Hangzhou between March 2004 and February 2007 were
consecutively eligible for enrollment.
We excluded patients who had received any investigational
drugs 30 days prior to the enrollment, such as progesterone,
estrogen and investigational compound, patients with severe
anoxic intracerebral damage or brain death, and patients
whose clinical condition was unstable (partial pressure of oxy-
gen < 60 mmHg or a systolic blood pressure < 90 mmHg, or
both). We also excluded pregnant patients and lactating
female patients, and those for whom there was doubt whether
the neurological status resulted from head trauma or acute or
chronic spinal cord injury.
The study was conducted in compliance with the clinical pro-
tocol approved by the Institutional Review Board and the eth-
ical committees of Clinical Medical College of Hangzhou,
according to Good Clinical Practice standards. Because of
the nature of patients' injuries, subjects in this clinical study
were incapable of granting informed consent. Investigators
therefore obtained informed consent from the subject's legal
guardian or health proxy before administering the drug. Given
the urgent circumstances, we were unable to obtain permis-
sion from a legal guardian or health proxy within the stipulated
time window for some patients (n = 53). Investigators there-
fore sought approval from the Institutional Review Board to
use deferred consent. If the Institutional Review Board deter-
mined that these regulatory criteria were satisfied, the investi-
gators were permitted to enroll subjects without consent.
When the drug was administered without proxy consent, the
Institutional Review Board was notified within 2 working days.
We continued to try to contact the proxy consent after drug
administration, and documented those attempts to the Institu-
tional Review Board. Once contacted, the family or legally
authorized representative was notified of the patient's enroll-
ment and asked to provide written approval for the patient's
continued participation. If attempts to contact proxy consent
were unsuccessful, or if the patient died before the family
could be contacted, we notified the Institutional Review Board
and placed a full report in the patient's record and study file.
Standard clinical management
After head computerized tomography scanning, the patients
were delivered to the neurosurgical intensive care unit of the
teaching hospital immediately or following surgical evacuation
of an intracranial hematoma. All patients received the standard
treatment for management of severe TBI based on the guide-
lines for the management of severe head injury of the American
Association of Neurologic Surgeons [20]. Particular emphasisAvailable online http://ccforum.com/content/12/2/R61
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was placed on the prevention and treatment of secondary
insults, the avoidance of intracranial hypertension, mainte-
nance of a normovolemic state as well as normothermia and
normoglycemia, with ventilation to maintain the oxygen pres-
sure at a minimum of 100 mmHg and the carbon dioxide pres-
sure at approximately 35 mmHg.
Randomization and medication administration
The prospective, randomized, placebo-controlled, double-
blind study was conducted in our neurosurgical intensive care
unit. Subjects enrolled in the study were randomized to receive
either progesterone (Tianjing Jinyao Pharmaceutical Co. Ltd,
Tianjing, China) or matching placebo within 8 hours of the
documented time of injury. Qualifying patients were randomly
assigned in a 1:1 manner to receive the matching treatment
with random numbers. Patients for the treatment group were
given progesterone at 1.0 mg/kg via intramuscular injection
and then once per 12 hours for 5 consecutive days. A single-
dosage volume equivalent to 0.05 ml/kg was used in each
subject. In a double-blind manner, progesterone and placebo
were supplied via identical-looking solutions in identical glass
vials with or without progesterone. The appearance, packag-
ing and administration of placebo and progesterone injections
were the same for the two groups. All patients, treating physi-
cians, nursing staff, and pharmacists were blinded throughout
the study period.
Clinical measurements
The ICP was monitored continuously using ICP monitoring
apparatus (CAMINO. MPM-1; Integra Co., San Diego, CA,
USA). A computerized tomography scan was obtained in all
patients at admission and this was categorized according to
the modified Marshall computerized tomography scan classifi-
cation: I, intracranial pathology not visible on the computerized
tomography scan; II, cisterns present with shift ≤ 5 mm;
lesions present, but no high-density or mixed-density lesions >
25 cm3, with bone fragments and foreign bodies; III, cisterns
compressed or absent, shift ≤ 5 mm, with no high-density or
mixed-density lesions > 25 cm3; IV, shift > 5 mm, with no high-
density or mixed-density lesions >25 cm3; V, any surgically
evacuated lesion; and VI, high-density or mixed-density lesions
>25 cm3 without surgical evacuation.
The patient's condition – body temperature, heart rate and res-
piratory rate, blood pressure, and pulse blood oxygen satura-
tion – was monitored continuously at the bedside with
monitoring apparatus (Hewlett-Packard, Palo Alto, CA, USA).
Daily evaluations of neurologic status over the initial 14-day
period were performed via the GCS score, adverse experi-
ences, surgical procedures, and intracranial complications.
Intake and output of fluids were also recorded.
Laboratory tests including hematology, the coagulation profile
and clinical chemistry were performed daily and then for 1
week after injury. A urine pregnancy test was performed at
enrollment for female patients (as necessary).
Neurologic outcome measurements
The neurologic outcome was evaluated according to the Glas-
gow Outcome Scale (GOS) score, which contains five levels
of outcome: good recovery, moderate disability, severe disabil-
ity, vegetative survival, or death. For statistical analysis, GOS
scores were dichotomized into favorable or unfavorable out-
comes. Patients in the upper two GOS outcome groups (good
recovery and moderate disability) were considered of favora-
ble outcome, and patients in the other groups (severe disabil-
ity, vegetative state, or death) were considered of unfavorable
outcome.
Secondary efficacy endpoints were the modified Functional
Independence Measure (FIM) score and mortality. Based on
previous reports [21,22], the modified FIM measurements of
disability in three areas of activity (domains of self-care, motor
function, and cognitive function) were chosen from the 18
items in the full FIM. Each of three items (expression, feeding,
and locomotion) includes four possible levels of function rang-
ing from total dependence (1) to independence (4). The total
modified FIM scores therefore ranged from 3 to 12. The
patients were assessed using the same measures both at 3
and 6 months in the follow-up protocol.
Statistical analysis
Descriptive statistics, including proportions, means and stand-
ard deviations, were compiled for all demographic and out-
come measures. Demographic and clinical data were analyzed
using Fisher's exact test. The statistical analyses were con-
ducted to assess the differences between the treatment group
and the control group on specific variables. Statistical analysis
was performed using contingency analysis (chi-squared) for
categorical data and Student's t test for continuous data. P <
0.05 was considered statistically significant. SPSS 11.0 soft-
ware package (SPSS Inc., Chicago IL, USA) was used for sta-
tistical analysis.
Results
Patients
Between March 2004 and February 2007, a total of 230
patients were screened in the present study. Of these, 159
patients meeting the protocol stipulation and condition were
recruited and randomized to receive either progesterone (n =
82) or placebo (n = 77). Data were available for 154 patients
(96%) at the 3-month follow-up and for 135 patients (84%) at
the 6-month follow-up. Nineteen patients (11%) were lost to
follow-up, three patients (1%) refused follow-up, and two
patients (1%) withdrew from the trial. No subjects were
enrolled in violation of the protocol stipulations (Figure 1).
The demographics of the progesterone and placebo groups
are presented in Table 1. The cohorts were well balanced withCritical Care    Vol 12 No 2    Xiao et al.
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Figure 1
Trial profile Trial profile.Available online http://ccforum.com/content/12/2/R61
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no significant differences between the two groups. The medi-
cation history of patients, medication administration, and med-
ical procedures were not significantly different among
treatment groups.
Glasgow Outcome Scale scores
The 3-month and 6-month GOS scores between the proges-
terone and placebo groups are summarized in Table 2. There
was a better recovery rate for the patients who were given pro-
gesterone than for those in the control group at 3-month fol-
low-up (P  = 0.044). A dichotomized analysis revealed
significant differences in neurologic outcome between the
treatment and control groups (Figure 2). The analysis using the
dichotomization of GOS scores at 3 months post injury
revealed a favorable outcome in 47% of the patients receiving
progesterone and in 31% of the placebo group (P = 0.034).
There was an unfavorable outcome in 53% of the patients
receiving progesterone and in 70% of the placebo group (P =
0.022). At 6-month follow-up, the dichotomized GOS scores
also showed a significant statistical difference between the
two groups, similar to those 3 months after injury. The percent-
age of favorable outcome was 58% for the patients who were
given progesterone and was 42% in the placebo group (P =
0.048). Forty-one percent of patients who were given proges-
terone and 57% of the placebo group exhibited an unfavorable
outcome (P = 0.048).
Subgroup analysis for women also showed a significant differ-
ence in the percentage of favorable outcome between the two
groups at 6-month follow-up (35% in the placebo group and
66% in the progesterone group, P = 0.036). The patients who
were given progesterone in the group with GCS of 6 to 8
showed a more favorable outcome (43%) compared with the
placebo group (28%) at 6-month follow-up (P = 0.044). There
was no significant difference, however, in dichotomized out-
comes in the group with GCS of 3 to 5 (P > 0.05).
Modified Functional Independence Measure scores
Figure 3 shows the modified FIM scores at 3-month and 6-
month follow-up. There was a significant difference in the
Table 1
Clinical and demographic characteristics between the two groups
Admission characteristic Placebo (n = 77) Progesterone (n = 82) P value
Males 57 (74) 58 (70) 0.64
Females 20 (25) 24 (29) 0.64
Mean (standard deviation) age (years) 31 (9) 30 (11) 0.52
Mean (standard deviation) time injury to administration (hours) 3.65 (1.46) 3.80 (2.03) 0.59
Mean (standard deviation) qualifying Glasgow Coma Scale score 6.1 (1.3) 6.0 (1.8) 0.68
Glasgow Coma Scale 3 to 5 20 (25) 22 (26) 0.90
Mechanism of injury
Motor vehicle 62 (80) 63 (76) 0.57
Fall 8 (10) 10 (12) 0.71
Assault 4 (5) 7 (8) 0.40
Other 3 (3) 2 (2) 0.59
Surgical procedures 24 (31) 22 (26) 0.54
Pupillary response
Bilaterally normal 26 (33) 26 (31) 0.78
Abnormal 51 (66) 56 (68) 0.78
Marshall computerized tomography scan classification
I 00
II 9 (11) 7 (8) 0.50
III 22 (28) 28 (34) 0.44
IV 13 (16) 12 (14) 0.69
V 24 (31) 22 (26) 0.54
VI 9 (11) 13 (15) 0.44
Data presented as n (%) unless indicated otherwise.Critical Care    Vol 12 No 2    Xiao et al.
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mean modified FIM score between two groups both at 3-
month and 6-month follow-up. At the 3-month follow-up, the
scores were 7.35 ± 1.89 for the placebo group and 8.02 ±
1.73 for the progesterone group (P < 0.05). Six months after
injury, the placebo group showed a score of 8.95 ± 1.05 and
the progesterone group presented 9.87 ± 1.17 (P < 0.01),
suggesting good functional outcome in the patients treated
with progesterone.
Mortality
During the 6 months of follow-up, a total of 40 patients (25%)
died in the present study (37 patients died during their hospi-
tal stay). Seventy percent of deaths occurred within 1 week
after trauma. Mortality was attributed to the heavy head injury
in each case. The mortality rate in the progesterone treatment
group was significantly lower at 6-month follow-up compared
with the placebo group (18% versus 32%, P = 0.039).
Intracranial pressure
Table 2
Comparison of Glasgow Outcome Scale scores between the progesterone and placebo groups patients at 3-month and 6-month 
follow-up
Glasgow Outcome Scale scores Progesterone (n = 82) Placebo (n = 77)
3 months
Good recovery 21 (25) 10 (12)
Moderate disability 18 (21) 14 (18)
Severe disability 16 (19) 13 (16)
Vegetative survival 13 (15) 16 (20)
Death 15 (18) 25 (32)
6 months
Good recovery 26 (31) 19 (24)
Moderate disability 22 (26) 14 (18)
Severe disability 9 (10) 11 (14)
Vegetative survival 10 (12) 8 (10)
Death 15 (18) 25 (32)
Data presented as n (%).
Figure 2
Dichotomized Glasgow Outcome Scale scores for patients receiving either progesterone or placebo Dichotomized Glasgow Outcome Scale scores for patients receiving either progesterone or placebo. There was a remarkably more favorable out-
come among patients who were given progesterone compared with patients receiving placebo (P = 0.034) 3 months postinjury. At 6-month follow-
up, the significant difference in the dichotomization of Glasgow Outcome Scale scores between the progesterone and placebo groups was similar 
to that after three-month injury (P = 0.048).Available online http://ccforum.com/content/12/2/R61
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Figure 4 shows the ICP in the progesterone group patients
and in the placebo group patients at 24 hours, 72 hours and
7 days after injury. The ICP was monitored continuously for 75
patients (47%), 40 in the progesterone group and 35 in the
placebo group. The mean ICP shows no apparent difference
at 24 hours after trauma between the two groups (progester-
one group, 22.1 ± 4.3 mmHg versus placebo group, 23.2 ±
4.6 mmHg; P = 0.121). At 72 hours and 7 days after injury, the
mean ICP of patients who were given progesterone was
slightly lower than those of patients who received placebo, but
the differences were not statistically significant (16.9 ± 3.8
mmHg and 14.8 ± 3.8 mmHg for progesterone-treated
patients versus 18.2 ± 5.1 mmHg and 15.9 ± 4.1 mmHg for
placebo-treated patients, respectively; P > 0.05).
Glasgow Coma Scale scores and clinical measurements
The mean GCS scores increased progressively in the two
groups during the 14-day acute phase of the study, with no
apparent differences among the treatment groups. Meanwhile,
there was no obvious difference in average body temperature,
heart and respiratory rates, blood pressure, pulse blood oxy-
gen saturation, and laboratory testing between the progester-
one and placebo groups.
Complications and adverse events
Progesterone was well tolerated in the treated patients with
acute severe TBI. No complication and adverse event associ-
ated with the administration of progesterone was found in this
clinical study during the hospitalization periods.
Discussion
The results of the present trial showed for the first time that
progesterone administration had a longer-term efficacy on
clinical outcomes in acute TBI patients. A significant increase
in the proportion of patients with a favorable outcome in the
progesterone group compared with the placebo group up to 6
months indicates the possibility of progesterone for treatment
of acute TBI. Moreover, there were more surviving TBI patients
in the treatment group than in the control group. Our results
suggest the efficacy of progesterone in the treatment of acute
severe TBI.
Previous reports showed the evidence of efficacy in TBI animal
models [8-14]. In the present study, the efficacy and safety of
Figure 3
Modified Functional Independence Measure scores for patients receiv- ing either progesterone or placebo Modified Functional Independence Measure scores for patients receiv-
ing either progesterone or placebo. Modified Functional Independence 
Measure (FIM) scores at 3-month and 6-month follow-up from patients 
receiving either progesterone or placebo show that the scores in the 
progesterone group were significantly higher than those in the placebo 
group at both 3-month and 6-month follow-up. Data expressed as the 
mean ± standard deviation. Different from the placebo group: *P < 
0.05, **P < 0.01.
Figure 4
Comparison of intracranial pressure between patients receiving either progesterone or placebo Comparison of intracranial pressure between patients receiving either progesterone or placebo. The mean intracranial pressure between the proges-
terone and placebo group patients shows no significant differences 24 hours, 72 hours and 7 days after injury between the two groups (P > 0.05). 
Data expressed as the mean ± standard deviation.Critical Care    Vol 12 No 2    Xiao et al.
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progesterone was confirmed in patients with acute severe TBI.
Furthermore, our results using the modified FIM and GOS
scores showed that progesterone administration remarkably
enhanced functional recovery 6 months after injury and
reduced the mortality of the patients with acute severe TBI
(GCS = 6 to 8), although there was no statistical significance
in the outcome improvement for GCS = 3 to 5 patients with
and without progesterone treatment. The evidence of
improved outcome for women patients also suggested, in part,
a beneficial efficacy and feasibility of progesterone in women
with TBI, in spite of the limited number of female patients in the
trial.
It is recognized that the pathophysiology of TBI is a multifacto-
rial process involved in a complex and interwoven series of
pathologic process following the onset of insult, such as
increased extracellular glutamate concentrations, increased
intracellular Ca2+, free radical overproduction and exacer-
bated inflammatory response. Medication targeted at a patho-
logical single injury factor could therefore not sufficiently
recover functional deficits following TBI. The ideal drugs
should be able to block multiple cellular events leading to brain
damage following TBI. Neuroprotective strategies currently
focus on acting on only one of the mechanisms. Some efforts
have been made, however, to combine agents or interventions
to increase the probability of success in this setting [23,24].
Nevertheless, the use of a single pharmacologic agent or pro-
cedure to slow or block damaging chemicals that are released
after brain injury is highly desirable.
Progesterone has several features that make it an attractive
potential drug candidate for TBI. First, progesterone could
protect against brain damage via multiple mechanisms[13,15-
18]. The pharmacokinetics of progesterone and its pattern of
adverse reactions are well known since the drug has been
safely used for a long time [25,26]. Second, with a wide ther-
apeutic window of progesterone, a single bolus given up to 24
hours post injury may significantly reduce cerebral edema [7].
Third, progesterone may rapidly cross the blood–brain barrier
and reach equilibrium with the plasma within 1 hour of admin-
istration [27-29]. Administration of progesterone soon after
TBI would probably benefit the recovery of the patient.
In the present double-blind trial, progesterone or placebo was
dissolved in the same camellia oil and taken daily for 5 days by
patients with acute TBI. Those patients administered proges-
terone experienced significant improvements in functioning
outcome, indicating neuroprotective properties of progester-
one in acute severe TBI. There was no adverse event after
administration of progesterone and no further late toxicity up
to 6 months in the trial.
Goss and colleagues suggested that low and moderate doses
of progesterone (4 to 8 mg/kg) were optimal for facilitating
recovery of select behaviors, and that postinjury progesterone
treatment permitted a wider dose range than preinjury treat-
ment in rats with medial frontal cortical contusions [30]. In
addition, 5 days of postinjury progesterone treatment are
needed to reduce significantly the neuropathological and
behavioral abnormalities found in a rodent model of TBI [13].
Wright and colleagues used intravenous progesterone at a
dose of 0.71 mg/kg, followed by 0.5 mg/kg progesterone per
12 hours during the 3 following days, which appeared safe in
the treatment of TBI patients [19]. In our study, the patients
were received a single intramuscular injection of 1.0 mg/kg
progesterone and the same dose per 12 hours for 5 consecu-
tive days. The results in our trial showed that single higher-
dose progesterone as protective therapy did not lead to any
serious side effects. No obvious symptoms of hormone reac-
tion were observed in our study. Accordingly, it can be antici-
pated that progesterone may be a promising treatment for
severe TBI patients as it is inexpensive, widely available and
has a long track record of safe use in humans to treat other
diseases.
The data in the present study provide very encouraging and
favorable conditions that could lead to the assessment of
GOS and FIM scores in TBI patients in a clinical trial. The
GOS score, although useful, provides only a global assess-
ment of function and dependence; it may not differentiate spe-
cific difference in cognitive function, motor function, or daily
activities. The modified FIM score selects only three items from
the 18-item score, and also distinguishes only four (as
opposed to seven) levels of function. Subtle or complex defi-
ciencies, particularly in cognitive function, may not have been
identified in the dataset. A deficiency in using any one scale to
measure outcome is that it is limited in its scope of measure-
ment. The present clinical study was therefore designed to
evaluated functional outcome according to the GOS and the
modified FIM score.
Intracranial hypertension has been considered an important
factor affecting the outcome of the patients with acute severe
TBI. Progesterone administration showed to decrease cere-
bral edema [9]. In an experimental study with male rats, there
was a linear correlation between the serum progesterone level
and brain edema after experimental TBI. The higher the serum
progesterone level, the lower the cerebral edema [31]. In the
current trial, however, no statistically significant difference was
found in ICP monitoring between the groups given progester-
one or placebo. It seems that progesterone treatment has little
effect on directly reducing the ICP of patients with acute
severe TBI.
As a result of randomization, all of these parameters were
homogeneous between the progesterone and placebo groups
in our clinical trial. Nevertheless, some limitations are observed
in the current study. The results could be influenced by a sin-
gle-center trial and local perioperative standard of care. There-
fore, it is necessary to use a sufficient power to assessAvailable online http://ccforum.com/content/12/2/R61
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progesterone's effects on neurologic outcomes. Our result of
the significant differences in outcomes between two groups of
patients emphasizes the potential value of using GOS and FIM
to tailor progesterone administration and the likelihood of
observing similar differences in a larger patient population;
however, the possibility exists that a statistical error may have
occurred because of an inadequate sample size. Further
studies are needed to determine the mechanisms of action
underlying the neurologic effect observed.
Conclusion
The present pilot study indicated that the use of progesterone
may significantly improve neurologic outcome of patients suf-
fering severe TBI up to 6 months after injury, providing a poten-
tial benefit to the treatment of acute severe TBI patients. Our
results strongly support further large, multicenter clinical trials
to examine the ways in which progesterone is achieving the
profound neurologic effect and to decipher optimal conditions
in which it can be used to lengthen the duration of and improve
the degree of neuroprotection.
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